Pemphigus Vulgaris - Pipeline Review, H1 2018

  • ID: 4540586
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • arGEN-X BV
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc
  • MORE
Pemphigus Vulgaris - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Pipeline Review, H1 2018, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.

Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights:

This latest pipeline guide Pemphigus Vulgaris - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Discovery and Unknown stages are 1, 4, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • arGEN-X BV
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc
  • MORE
Introduction

Report Coverage

Pemphigus Vulgaris - Overview

Pemphigus Vulgaris - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pemphigus Vulgaris - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pemphigus Vulgaris - Companies Involved in Therapeutics Development

arGEN-X BV

Biogen Inc

HanAll Biopharma Co Ltd

Immunomedics Inc

Novartis AG

Principia Biopharma Inc

Pemphigus Vulgaris - Drug Profiles

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRN-1008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYNT-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAY-736 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veltuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pemphigus Vulgaris - Dormant Projects

Pemphigus Vulgaris - Discontinued Products

Pemphigus Vulgaris - Product Development Milestones

Featured News & Press Releases

Feb 13, 2018: FDA Grants Priority Review for Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris

Dec 11, 2017: argenx reports positive top line results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

Nov 02, 2017: Argenx to Host KOL Breakfast Symposium on Pemphigus Vulgaris

Oct 30, 2017: Argenx Launches Phase I Trial with Subcutaneous Formulation of ARGX-

Sep 26, 2017: argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris

Sep 18, 2017: Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting

Jul 11, 2017: Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA for Treatment of Pemphigus Vulgaris

Mar 24, 2017: FDA grants breakthrough therapy designation for MabThera/Rituxan (rituximab) in pemphigus vulgaris

Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology

Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pemphigus Vulgaris - Pipeline by arGEN-X BV, H1 2018

Pemphigus Vulgaris - Pipeline by Biogen Inc, H1 2018

Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, H1 2018

Pemphigus Vulgaris - Pipeline by Immunomedics Inc, H1 2018

Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2018

Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc, H1 2018

Pemphigus Vulgaris - Dormant Projects, H1 2018

Pemphigus Vulgaris - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • arGEN-X BV
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll